QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Tackles Chronic Liver Disease, A Major Cause Of Death 0 comments
    Jul 30, 2013 5:37 PM | about stocks: ISCO

    Stem cell technology has unlocked a world of potential treatments for almost every kind of disease. International Stem Cell offers an especially valuable foundation for such treatments through its development of parthenogenetic stem cells (hpSC), non-embryonic histocompatible human stem cells. Parthenogenesis promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. This is because parthenogenesis utilizes unfertilized human eggs to create stem cells that can be immune-matched to millions of people, meaning that a relatively small number of hpSC lines could provide sufficient immune-matched cells to cover a large percentage of the world's population.

    ISCO scientists are now performing research to verify that such parthenogenetic stem cell lines can be successfully used to treat a variety of diseases, including chronic liver disease. Chronic liver disease (including hepatitis C) is the third most common cause of death due to chronic diseases in persons 35 to 64 years old. Roughly 3 million Americans are chronically infected with the hepatitis C virus, and approximately 12,000 Americans die annually from the disease. Cirrhosis and hepatitis taken together claim over 30,000 lives annually in the U.S. alone, and health care costs for chronic and acute liver disease in the U.S. are estimated to range from $60 billion to over $100 billion.

    The company's scientific team is developing better methods to create pure populations of hepatocyte, the cells that make up most liver tissue, for use in transplantation, using HLA homozygous parthenogenetic stem cell lines to avoid the cells being immune rejected. UniStemCell bank, established by ISCO, is the life science industry's first collection of non-embryonic histocompatible human stem cells available for research and commercial use.

    For additional information, visit www.InternationalStemCell.com

    Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.